XML 97 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Deferred income tax assets:    
Net operating loss carryforward $ 96,811,786 $ 88,746,869
Research and orphan drug credits 54,937,994 53,152,849
Capitalized research costs 11,861,613 10,748,355
Capitalized start-up costs 339,138 532,931
Patent amortization 27,071 42,541
Stock-based compensation 6,699,628 7,324,617
Accrued bonus 25,356 704,974
Operating lease liabilities 18,394 222,452
Other 1,303 87,097
Gross deferred income tax assets 170,722,283 161,562,685
Valuation allowance (170,722,283) (161,351,398)
Net deferred income tax assets 211,287
Deferred income tax liabilities:    
Operating lease right-of-use assets   (211,287)
Gross deferred income tax liabilities (211,287)
Net deferred income tax asset/(liability)